Game-Changer for Lung Cancer?

Big news in cancer treatment: Amgen’s new drug Imdelltra just cut the risk of death by 40% for small cell lung cancer patients compared to regular chemo! Patients lived over 5 months longer on average, and had fewer serious side effects (27% vs 62%). Plus, people felt better—less coughing and shortness of breath. These results could lock in FDA approval for Imdelltra. Feels like a huge win for patients and families facing this tough diagnosis. #LungCancer #MedicalBreakthrough #CancerResearch #Health